X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA LUPIN LTD SHASUN PHARMA/
LUPIN LTD
 
P/E (TTM) x 123.9 16.6 747.2% View Chart
P/BV x 8.5 3.9 220.9% View Chart
Dividend Yield % 0.2 0.8 29.2%  

Financials

 SHASUN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
LUPIN LTD
Mar-16
SHASUN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs942,127 4.4%   
Low Rs461,294 3.5%   
Sales per share (Unadj.) Rs214.2304.1 70.4%  
Earnings per share (Unadj.) Rs5.350.4 10.6%  
Cash flow per share (Unadj.) Rs15.860.7 26.1%  
Dividends per share (Unadj.) Rs1.007.50 13.3%  
Dividend yield (eoy) %1.40.4 326.3%  
Book value per share (Unadj.) Rs53.3243.8 21.9%  
Shares outstanding (eoy) m56.62450.58 12.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.6 5.8%   
Avg P/E ratio x13.133.9 38.6%  
P/CF ratio (eoy) x4.428.2 15.7%  
Price / Book Value ratio x1.37.0 18.7%  
Dividend payout %18.714.9 125.9%   
Avg Mkt Cap Rs m3,958770,740 0.5%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m2,16421,077 10.3%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m12,127137,016 8.9%  
Other income Rs m2291,877 12.2%   
Total revenues Rs m12,356138,893 8.9%   
Gross profit Rs m1,00937,535 2.7%  
Depreciation Rs m5944,635 12.8%   
Interest Rs m415446 93.0%   
Profit before tax Rs m23034,330 0.7%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-7311,536 -0.6%   
Profit after tax Rs m30222,707 1.3%  
Gross profit margin %8.327.4 30.4%  
Effective tax rate %-31.733.6 -94.2%   
Net profit margin %2.516.6 15.0%  
BALANCE SHEET DATA
Current assets Rs m6,88497,790 7.0%   
Current liabilities Rs m8,45653,872 15.7%   
Net working cap to sales %-13.032.1 -40.4%  
Current ratio x0.81.8 44.9%  
Inventory Days Days6285 72.8%  
Debtors Days Days108121 88.7%  
Net fixed assets Rs m4,97086,379 5.8%   
Share capital Rs m113901 12.6%   
"Free" reserves Rs m2,875105,735 2.7%   
Net worth Rs m3,020109,844 2.7%   
Long term debt Rs m1,81753,739 3.4%   
Total assets Rs m13,347224,378 5.9%  
Interest coverage x1.677.9 2.0%   
Debt to equity ratio x0.60.5 123.0%  
Sales to assets ratio x0.90.6 148.8%   
Return on assets %5.410.3 52.1%  
Return on equity %10.020.7 48.4%  
Return on capital %13.321.2 62.8%  
Exports to sales %46.449.1 94.5%   
Imports to sales %14.27.4 191.4%   
Exports (fob) Rs m5,62267,244 8.4%   
Imports (cif) Rs m1,72810,199 16.9%   
Fx inflow Rs m5,84371,405 8.2%   
Fx outflow Rs m2,17317,807 12.2%   
Net fx Rs m3,66953,598 6.8%   
CASH FLOW
From Operations Rs m398-3,690 -10.8%  
From Investments Rs m-1,635-69,434 2.4%  
From Financial Activity Rs m1,30958,126 2.3%  
Net Cashflow Rs m71-14,998 -0.5%  

Share Holding

Indian Promoters % 39.2 46.6 84.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 31.9 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.1 392.1%  
Shareholders   20,750 98,259 21.1%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   VENUS REMEDIES  MERCK LTD  SANOFI INDIA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS